Berindan-Neagoe I - Search Results

1

A Looking-Glass of Non-coding RNAs in oral cancer.

Irimie AI, Braicu C, Sonea L, Zimta AA, Cojocneanu-Petric R, Tonchev K, Mehterov N, Diudea D, Buduru S, Berindan-Neagoe I. Irimie AI, et al. Int J Mol Sci. 2017 Dec 5;18(12):2620. doi: 10.3390/ijms18122620. Int J Mol Sci. 2017. PMID: 29206174 Free PMC article. Review.

2

p53 gene therapy using RNA interference.

Berindan-Neagoe I, Balacescu O, Burz C, Braicu C, Balacescu L, Tudoran O, Cristea V, Irimie A. Berindan-Neagoe I, et al. J BUON. 2009 Sep;14 Suppl 1:S51-9. J BUON. 2009. PMID: 19785070 Review.

3

Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters.

Burz C, Berindan-Neagoe I, Balacescu O, Todor N, Pelau D, Floares C, Kacso G, Tanaselia C, Ursu M, Vlase L, Leucuta SE, Cristea V, Irimie A. Burz C, et al. J BUON. 2010 Apr-Jun;15(2):263-9. J BUON. 2010. PMID: 20658719

4

Early transcriptional pattern of angiogenesis induced by EGCG treatment in cervical tumour cells.

Tudoran O, Soritau O, Balacescu O, Balacescu L, Braicu C, Rus M, Gherman C, Virag P, Irimie F, Berindan-Neagoe I. Tudoran O, et al. J Cell Mol Med. 2012 Mar;16(3):520-30. doi: 10.1111/j.1582-4934.2011.01346.x. J Cell Mol Med. 2012. PMID: 21609393 Free PMC article.

5

The clinical implications of platelet derived growth factor B, vascular endothelial growth factor and basic fibroblast growth factor in colorectal cancer.

Ionescu C, Berindan-Neagoe I, Burz C, Balacescu O, Balacescu L, Tudoran O, Asztalos R, Irimie A. Ionescu C, et al. J BUON. 2011 Apr-Jun;16(2):274-6. J BUON. 2011. PMID: 21766497

6

Non-coding RNAs as theranostics in human cancers.

Redis RS, Berindan-Neagoe I, Pop VI, Calin GA. Redis RS, et al. J Cell Biochem. 2012 May;113(5):1451-9. doi: 10.1002/jcb.24038. J Cell Biochem. 2012. PMID: 22213511 Free PMC article. Review.

7

Quantitative mRNA expression of genes involved in angiogenesis, coagulation and inflammation in multiforme glioblastoma tumoral tissue versus peritumoral brain tissue: lack of correlation with clinical data.

Berindan-Neagoe I, Chiorean R, Braicu C, Florian IS, Leucuta D, Crisan D, Cocis A, Balacescu O, Irimie A. Berindan-Neagoe I, et al. Eur Cytokine Netw. 2012 Jun;23(2):45-55. doi: 10.1684/ecn.2012.0302. Eur Cytokine Netw. 2012. PMID: 22591734 Free article.

8

Early apoptosis signals induced by a low dose of epigallocatechin 3-gallate interfere with apoptotic and cell death pathways.

Berindan-Neagoe I, Braicu C, Tudoran O, Balacescu O, Irimie A. Berindan-Neagoe I, et al. J Nanosci Nanotechnol. 2012 Mar;12(3):2113-9. doi: 10.1166/jnn.2012.5701. J Nanosci Nanotechnol. 2012. PMID: 22755028

9

Combining the chemotherapeutic effects of epigallocatechin 3-gallate with siRNA-mediated p53 knock-down results in synergic pro-apoptotic effects.

Berindan-Neagoe I, Braicu C, Irimie A. Berindan-Neagoe I, et al. Int J Nanomedicine. 2012;7:6035-47. doi: 10.2147/IJN.S36523. Epub 2012 Dec 12. Int J Nanomedicine. 2012. PMID: 23251091 Free PMC article.

10

Novel cellular and molecular approaches to stratification and treatment of colorectal cancer.

Miron N, Susman S, Balacescu O, Buiga R, Berindan-Neagoe I, Cristea V, Balacescu L, Manolescu V, Ciuleanu TE. Miron N, et al. J Gastrointestin Liver Dis. 2012 Dec;21(4):413-21. J Gastrointestin Liver Dis. 2012. PMID: 23256125 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

365 results

Search Page